Astellas Pharma Inc. (ALPMY)

11.00 +0.25 (+2.33%) 收市：03:50PM EDT

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 14,754

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Naoki Okamura BSc	President, CEO & Director	949.88k	無	1962
Mr. Atsushi Kitamura	Chief Financial Officer	無	無	無
Nobue Yasuda	General Manager of Finance & Accounting Department	無	無	無
Mr. Yoshitsugu Shitaka Ph.D.	Chief Scientific Officer & Senior Managing Executive Officer	無	無	無
Ms. Catherine B. Levitt	General Counsel	無	無	無
Mr. Katsuyoshi Sugita	Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director	無	無	1967
Mr. Stig Ogata	Vice President of Corporate Communications	無	無	無
Ms. Collette Taylor	Senior Vice President of Human Resources	無	無	1963
Ms. Tatjana Dragovic	Senior VP and Head of Ethics & Compliance	無	無	無
Mr. Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

公司管治

截至 2024年7月1日 止，Astellas Pharma Inc. 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：1；董事會：2；股東權利：6；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。